- Home
- BNRG vs NEUP Comparison
BNRG vs NEUP Comparison
Compare BNRG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- NEUP
- Stock Information
- Founded
- BNRG 2012
- NEUP 1996
- Country
- BNRG Israel
- NEUP United States
- Employees
- BNRG N/A
- NEUP N/A
- Industry
- BNRG
- NEUP
- Sector
- BNRG
- NEUP
- Exchange
- BNRG Nasdaq
- NEUP Nasdaq
- Market Cap
- BNRG 10.0M
- NEUP 9.3M
- IPO Year
- BNRG 2022
- NEUP N/A
- Fundamental
- Price
- BNRG $1.31
- NEUP $5.04
- Analyst Decision
- BNRG
- NEUP Strong Buy
- Analyst Count
- BNRG 0
- NEUP 1
- Target Price
- BNRG N/A
- NEUP $21.00
- AVG Volume (30 Days)
- BNRG 36.5K
- NEUP 21.4K
- Earning Date
- BNRG 03-04-2025
- NEUP 05-15-2025
- Dividend Yield
- BNRG N/A
- NEUP N/A
- EPS Growth
- BNRG N/A
- NEUP N/A
- EPS
- BNRG N/A
- NEUP N/A
- Revenue
- BNRG N/A
- NEUP $662,715.00
- Revenue This Year
- BNRG N/A
- NEUP N/A
- Revenue Next Year
- BNRG N/A
- NEUP N/A
- P/E Ratio
- BNRG N/A
- NEUP N/A
- Revenue Growth
- BNRG N/A
- NEUP N/A
- 52 Week Low
- BNRG $0.60
- NEUP $2.12
- 52 Week High
- BNRG $3.27
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- BNRG 50.12
- NEUP N/A
- Support Level
- BNRG $1.31
- NEUP N/A
- Resistance Level
- BNRG $1.42
- NEUP N/A
- Average True Range (ATR)
- BNRG 0.13
- NEUP 0.00
- MACD
- BNRG 0.00
- NEUP 0.00
- Stochastic Oscillator
- BNRG 62.50
- NEUP 0.00
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.